van Eyk HJ, et al. - In a placebo-controlled trial including South Asian patients with type 2 diabetes, researchers determined the impact on ectopic fat deposition and HbA1c of liraglutide administered for 26 weeks. Participants (n=47) randomly received liraglutide (1.8 mg/day) or placebo added to standard care. MRI was used to evaluate abdominal subcutaneous, visceral, epicardial and paracardial adipose tissue volume at baseline and following 26 weeks of treatment. Proton magnetic resonance spectroscopy was performed to assess myocardial and hepatic triglyceride content. The impacts of liraglutide on ectopic fat and HbA1c were not evident in the intention-to-treat analysis. A reduction in visceral adipose tissue volume, which was related to improved glycemic control in South Asians, was reported in relation to treatment with liraglutide, a finding in per-protocol analysis.